Janssen Biotech, Inc.
Johnson & Johnson Innovative Medicine is dedicated to developing groundbreaking medicines and medical technologies across various healthcare areas, with a focus on transforming health and improving patient lives through science and compassion. The company collaborates globally to bring innovative solutions to market faster, addressing complex diseases and unmet medical needs. They emphasize economic responsibility by ensuring fair pricing, local value, and accessibility of medicines to benefit patients and societies worldwide. Their mission includes preventing, intercepting, and curing diseases, especially in early childhood, through innovative and collaborative approaches. The company also focuses on social impact, working with partners to improve health outcomes and health equity.
Industries
Nr. of Employees
medium (51-250)
Janssen Biotech, Inc.
Products
Immunology
Janssen Biotech develops treatments targeting immune system disorders, focusing on conditions like rheumatoid arthritis and psoriasis.
Oncology
Janssen Biotech offers therapies for various cancers, aiming to improve patient outcomes through innovative cancer treatments.
Cardiovascular & Metabolism
Janssen Biotech provides medications addressing cardiovascular diseases and metabolic disorders, enhancing patient care in these areas.
Neuroscience
Janssen Biotech focuses on neurological disorders, developing treatments for conditions such as schizophrenia and Alzheimer's disease.
Infectious Diseases & Vaccines
Janssen Biotech works on treatments and vaccines for infectious diseases, contributing to global health efforts.
Pulmonary Hypertension
Janssen Biotech offers therapies for pulmonary hypertension, aiming to improve the quality of life for affected patients.
Immunology
Janssen Biotech develops treatments targeting immune system disorders, focusing on conditions like rheumatoid arthritis and psoriasis.
Oncology
Janssen Biotech offers therapies for various cancers, aiming to improve patient outcomes through innovative cancer treatments.
Cardiovascular & Metabolism
Janssen Biotech provides medications addressing cardiovascular diseases and metabolic disorders, enhancing patient care in these areas.
Neuroscience
Janssen Biotech focuses on neurological disorders, developing treatments for conditions such as schizophrenia and Alzheimer's disease.
Infectious Diseases & Vaccines
Janssen Biotech works on treatments and vaccines for infectious diseases, contributing to global health efforts.
Pulmonary Hypertension
Janssen Biotech offers therapies for pulmonary hypertension, aiming to improve the quality of life for affected patients.
Services
Collaboration programs with academic institutions, biotech companies and research organizations to co-develop discoveries and accelerate translational research.
Engagement with patient organizations to inform clinical development, improve patient resources and co-design support programs.
Tools and services to connect patients and clinicians with active clinical studies and support trial enrollment.
Programs and informational resources to help patients access approved treatments and understand affordability and reimbursement options.
Mechanisms to provide investigational therapies to patients prior to approval where permitted by regulation.
Engagement with payers, governments and health systems to negotiate coverage, support reimbursement and implement local pricing strategies.
Collaboration programs with academic institutions, biotech companies and research organizations to co-develop discoveries and accelerate translational research.
Engagement with patient organizations to inform clinical development, improve patient resources and co-design support programs.
Tools and services to connect patients and clinicians with active clinical studies and support trial enrollment.
Programs and informational resources to help patients access approved treatments and understand affordability and reimbursement options.
Mechanisms to provide investigational therapies to patients prior to approval where permitted by regulation.
Engagement with payers, governments and health systems to negotiate coverage, support reimbursement and implement local pricing strategies.
Expertise Areas
- Oncology
- Immunology
- Neuroscience
- Cardiopulmonary
Key Technologies
- Medicinal chemistry and compound synthesis
- Monoclonal antibody and biologic engineering
- Next-generation clinical trial platforms and trial-matching tools
- Biomarker discovery and validation methods
News & Updates
A significant survival benefit in patients with EGFR-mutated non-small cell lung cancer.
Johnson & Johnson received FDA approval for IMAAVY™ (nipocalimab-aahu), a new treatment for MG.
U.S. FDA approved TREMFYA® (guselkumab), an IL-23 inhibitor for Crohn’s disease.
A landmark acquisition to strengthen neuroscience leadership.
A significant survival benefit in patients with EGFR-mutated non-small cell lung cancer.
Johnson & Johnson received FDA approval for IMAAVY™ (nipocalimab-aahu), a new treatment for MG.
U.S. FDA approved TREMFYA® (guselkumab), an IL-23 inhibitor for Crohn’s disease.
A landmark acquisition to strengthen neuroscience leadership.